CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
Gilbert, Arizona, United States and 71 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Chandler, Arizona, United States and 210 other locations
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...
Phase 2
Gilbert, Arizona, United States and 123 other locations
in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung...
Phase 1, Phase 2
Phoenix, Arizona, United States and 58 other locations
with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NS...
Phase 1, Phase 2
Phoenix, Arizona, United States and 87 other locations
KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung...
Phase 3
Gilbert, Arizona, United States and 156 other locations
with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung ...
Phase 3
Chandler, Arizona, United States and 262 other locations
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sit...
Phase 3
Goodyear, Arizona, United States and 44 other locations
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON...
Phase 1, Phase 2
Gilbert, Arizona, United States and 93 other locations
The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab a...
Phase 1
Goodyear, Arizona, United States and 23 other locations
Clinical trials
Research sites
Resources
Legal